Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 431

1.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Jun 6. doi: 10.1007/s00259-019-04358-9. [Epub ahead of print]

PMID:
31172212
2.

The effect of using pazopanib with food vs fasted on pharmacokinetics, patient safety and preference (DIET study).

Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.

Clin Pharmacol Ther. 2019 May 24. doi: 10.1002/cpt.1515. [Epub ahead of print]

PMID:
31125423
3.

Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease.

Weidema ME, Versleijen-Jonkers YMH, Flucke UE, Desar IME, van der Graaf WTA.

Crit Rev Oncol Hematol. 2019 Jun;138:120-131. doi: 10.1016/j.critrevonc.2019.04.010. Epub 2019 Apr 15. Review.

4.

Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).

Driessen CM, Ham JC, Te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, van Herpen CM.

Cancers (Basel). 2019 Apr 17;11(4). pii: E551. doi: 10.3390/cancers11040551.

5.

Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.

Ham JC, Driessen CM, Hendriks MP, Fiets E, Kreike B, Hoeben A, Slingerland M, van Opstal CC, Kullberg BJ, Jonker MA, Adang EM, Kaanders JH, van der Graaf WT, van Herpen CM.

Eur J Cancer. 2019 May;113:32-40. doi: 10.1016/j.ejca.2019.02.013. Epub 2019 Apr 6.

PMID:
30965213
6.

Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.

Vlenterie M, Oyen WJ, Steeghs N, Desar IME, Verheijen RB, Koenen AM, Grootjans W, DE Geus-Oei LF, VAN Erp NP, VAN DER Graaf WT.

Anticancer Res. 2019 Mar;39(3):1309-1316. doi: 10.21873/anticanres.13243.

PMID:
30842163
7.

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.

Vos M, Sleijfer S, Litière S, Touati N, Duffaud F, van der Graaf WT, Gelderblom H.

Acta Oncol. 2019 Jun;58(6):872-879. doi: 10.1080/0284186X.2019.1581376. Epub 2019 Mar 4.

PMID:
30831041
8.

The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.

Verspoor FGM, Mastboom MJL, Hannink G, van der Graaf WTA, van de Sande MAJ, Schreuder HWB.

Bone Joint J. 2019 Mar;101-B(3):272-280. doi: 10.1302/0301-620X.101B3.BJJ-2018-0804.R1.

PMID:
30813787
9.

Caregivers' burden and fatigue during and after patients' treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study.

Langenberg SMCH, van Herpen CML, van Opstal CCM, Wymenga ANM, van der Graaf WTA, Prins JB.

Support Care Cancer. 2019 Feb 22. doi: 10.1007/s00520-019-04700-9. [Epub ahead of print]

PMID:
30796519
10.

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.

Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen RHJ, Van Erp NP, Gelderblom H, Van der Graaf WT, Gronchi A.

Clin Cancer Res. 2019 Mar 1;25(5):1479-1485. doi: 10.1158/1078-0432.CCR-18-2748. Epub 2019 Feb 14.

PMID:
30765389
11.

Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.

Sebio A, Constantinidou A, Benson C, Antoniou G, Messiou C, Miah A, Zaidi S, Petruckevitch A, Al-Muderis O, Thway K, VAN DER Graaf WT, Jones RL.

Anticancer Res. 2019 Jan;39(1):347-351. doi: 10.21873/anticanres.13118.

PMID:
30591479
12.

Online support community for adolescents and young adults (AYAs) with cancer: user statistics, evaluation, and content analysis.

Kaal SE, Husson O, van Dartel F, Hermans K, Jansen R, Manten-Horst E, Servaes P, van de Belt TH, Engelen LJ, Prins JB, Verberne S, van der Graaf WT.

Patient Prefer Adherence. 2018 Dec 6;12:2615-2622. doi: 10.2147/PPA.S171892. eCollection 2018.

13.

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.

Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.

Head Neck. 2019 Feb;41(2):488-494. doi: 10.1002/hed.25434. Epub 2018 Dec 7.

PMID:
30536479
14.

Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry.

Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ, Desar IME, van der Graaf WTA, Bonenkamp JJ, Reyners AKL, van Etten B.

Eur J Surg Oncol. 2019 Mar;45(3):410-415. doi: 10.1016/j.ejso.2018.09.013. Epub 2018 Oct 16.

PMID:
30416078
15.

Age-related sarcoma patient experience: results from a national survey in England.

Younger E, Husson O, Bennister L, Whelan J, Wilson R, Roast A, Jones RL, van der Graaf WT.

BMC Cancer. 2018 Oct 17;18(1):991. doi: 10.1186/s12885-018-4866-8.

16.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

17.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

18.

Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden.

Langenberg SMCH, Reyners AKL, Wymenga ANM, Sieling GCM, Veldhoven CMM, van Herpen CML, Prins JB, van der Graaf WTA.

Acta Oncol. 2019 Feb;58(2):191-199. doi: 10.1080/0284186X.2018.1518592. Epub 2018 Oct 3.

PMID:
30280630
19.

Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management.

Owen C, Constantinidou A, Miah AB, Thway K, Fisher C, Benson C, Zaidi S, Messiou C, VAN DER Graaf WTA, Jones RL.

Anticancer Res. 2018 Sep;38(9):5275-5282. doi: 10.21873/anticanres.12853. Review.

PMID:
30194178
20.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

21.

Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma.

Chew W, Benson C, Thway K, Hayes A, Miah A, Zaidi S, Lee ATJ, Messiou C, Fisher C, van der Graaf WT, Jones RL.

Med Oncol. 2018 Sep 5;35(11):138. doi: 10.1007/s12032-018-1192-6.

22.

Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care?

Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, Hayes AJ, Miah A, van Houdt W, Zaidi S, Smith M, Williams J, Jones RL, van der Graaf WTA.

Support Care Cancer. 2019 Mar;27(3):965-980. doi: 10.1007/s00520-018-4386-8. Epub 2018 Aug 28.

23.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

24.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

van Broekhoven DLM, Verschoor AJ, van Dalen T, Grünhagen DJ, den Bakker MA, Gelderblom H, Bovee JVMG, Haas RLM, Bonenkamp HJ, van Coevorden F, Ten Oever D, van der Graaf WTA, Flucke UE, Pras E, Reyners AKL, Westermann AM, Oldenburger F, Verhoef C, Steeghs N.

Sarcoma. 2018 Jun 21;2018:5982575. doi: 10.1155/2018/5982575. eCollection 2018.

25.

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.

Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.

26.

Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study.

Timbergen MJM, van de Poll-Franse LV, Grünhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, Husson O.

Qual Life Res. 2018 Dec;27(12):3097-3111. doi: 10.1007/s11136-018-1931-3. Epub 2018 Jul 16. Review.

27.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

28.

Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma.

van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG.

Mol Cancer Ther. 2018 Jul;17(7):1365-1380. doi: 10.1158/1535-7163.MCT-17-1131. Review.

PMID:
29967215
29.

Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.

Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx MAW, Takes RP, Kaanders JHAM, Groenen PJTA, Flucke UE, van Herpen CML.

Oral Oncol. 2018 Jul;82:29-33. doi: 10.1016/j.oraloncology.2018.04.022. Epub 2018 May 11.

30.

Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies.

Husson O, Huijgens PC, van der Graaf WTA.

Blood. 2018 Jul 26;132(4):385-392. doi: 10.1182/blood-2017-11-778555. Epub 2018 Jun 12. Review.

PMID:
29895664
31.

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.

Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, Thomas K, Moskovic E, Szucs Z, Benson C, Messiou C.

Clin Sarcoma Res. 2018 May 14;8:13. doi: 10.1186/s13569-018-0100-3. eCollection 2018.

32.

Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry.

Mols F, Schoormans D, Smit JWA, Netea-Maier RT, Links TP, van der Graaf WTA, Husson O.

Head Neck. 2018 Oct;40(10):2235-2245. doi: 10.1002/hed.25325. Epub 2018 May 13.

PMID:
29756245
33.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823. No abstract available.

34.

Health-Related Quality of Life in Patients With Sarcoma: Enhancing Personalized Medicine.

Younger E, Wilson R, van der Graaf WTA, Husson O.

J Clin Oncol. 2018 Jun 1;36(16):1642-1643. doi: 10.1200/JCO.2018.77.9819. Epub 2018 Apr 18. No abstract available.

PMID:
29668370
35.

Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.

van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW.

Br J Surg. 2018 Jul;105(8):1020-1027. doi: 10.1002/bjs.10809. Epub 2018 Apr 17.

36.

Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.

Younger E, Litière S, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Jones RL, Gronchi A, van der Graaf WTA.

Oncologist. 2018 Oct;23(10):1250-1259. doi: 10.1634/theoncologist.2017-0598. Epub 2018 Apr 12.

PMID:
29650688
37.

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

McVeigh TP, Sundar R, Diamantis N, Kaye SB, Banerji U, Lopez JS, de Bono J, van der Graaf WTA, George AJ.

Eur J Cancer. 2018 May;95:20-29. doi: 10.1016/j.ejca.2018.02.028. Epub 2018 Mar 31.

38.

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.

Verschoor AJ, Litière S, Marréaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, Gronchi A, Gelderblom H.

Eur J Cancer. 2018 May;94:187-198. doi: 10.1016/j.ejca.2018.02.015. Epub 2018 Mar 22.

PMID:
29574364
39.

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.

Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL.

Oncotarget. 2018 Feb 14;9(17):13870-13883. doi: 10.18632/oncotarget.24493. eCollection 2018 Mar 2.

40.

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.

Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):448-454. doi: 10.1016/j.clon.2018.02.065. Epub 2018 Mar 15.

41.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Aug;57(8):1117-1126. doi: 10.1080/0284186X.2018.1449248. Epub 2018 Mar 9.

PMID:
29521151
42.

Systemic Treatment for Adults with Synovial Sarcoma.

Desar IME, Fleuren EDG, van der Graaf WTA.

Curr Treat Options Oncol. 2018 Mar 7;19(2):13. doi: 10.1007/s11864-018-0525-1. Review.

43.

A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.

Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF; PALGA Group, Jonker MA, Flucke UE, van Herpen CML.

Int J Cancer. 2018 Aug 15;143(4):758-766. doi: 10.1002/ijc.31353. Epub 2018 Mar 23.

44.

Systemic treatment in adult uterine sarcomas.

Desar IME, Ottevanger PB, Benson C, van der Graaf WTA.

Crit Rev Oncol Hematol. 2018 Feb;122:10-20. doi: 10.1016/j.critrevonc.2017.12.009. Epub 2017 Dec 14. Review.

45.

Young adults: a unique group in cancer epidemiological research.

Husson O, Lidington E, Younger E, van der Graaf WT.

Lancet Oncol. 2018 Feb;19(2):e72. doi: 10.1016/S1470-2045(18)30029-9. No abstract available.

PMID:
29413473
46.

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA.

Int J Cancer. 2018 Jun 15;142(12):2610-2620. doi: 10.1002/ijc.31286. Epub 2018 Feb 14.

47.

Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.

Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M, Fiets E, Oosting SF, Slingerland M, Hoeben A, Tesselaar MET, Jonker MA, Flucke UE; Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group, van der Graaf WTA, van Herpen CML.

Head Neck. 2018 Mar;40(3):605-613. doi: 10.1002/hed.25035. Epub 2017 Dec 22.

48.

Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.

Driessen CML, Groenewoud JMM, de Boer JP, Gelderblom H, van der Graaf WTA, Prins JB, Kaanders JHAM, van Herpen CML.

Support Care Cancer. 2018 Apr;26(4):1233-1242. doi: 10.1007/s00520-017-3946-7. Epub 2017 Dec 11.

49.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
50.

Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service.

Thewes B, Kaal SEJ, Custers JAE, Manten-Horst E, Jansen R, Servaes P, van der Graaf WTA, Prins JB, Husson O.

Support Care Cancer. 2018 May;26(5):1479-1487. doi: 10.1007/s00520-017-3975-2. Epub 2017 Nov 22.

Supplemental Content

Loading ...
Support Center